Online inquiry

IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13327MR)

This product GTTS-WQ13327MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TFPI gene. The antibody can be applied in Hemophilia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001032281.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7035
UniProt ID P10646
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ13327MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10000MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KRN-23
GTTS-WQ8386MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ9152MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMGN-289
GTTS-WQ14913MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ3665MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ15965MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ8063MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ14984MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SHR-1314
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW